Sun Pharma's Mixed Q2 Results Lead to Earnings Downgrades

Business Standard · stocks

Sun Pharma experienced a mixed performance in its July-September quarter, with its speciality and US businesses showing slower growth, while the Indian market saw acceleration. Despite this, many analysts remain optimistic about India's largest pharmaceutical company, which has a market capitalisation of ₹4.24 trillion. Following the Q2 results, near-term earnings projections and target prices were revised downwards. The company's share price initially rose but has since relinquished most of those gains.

सन फार्मा ने जुलाई-सितंबर तिमाही में मिली-जुलीThe performance दिखाई, जिसमें स्पेशियलिटी और US कारोबार में धीमीThe growth देखी गई, जबकि भारतीयThe market मेंThe acceleration मिला। इसके बावजूद, कईThe analysts भारत की सबसे बड़ीThe pharmaceutical कंपनी को लेकरThe optimistic बने हुए हैं, जिसकाThe market capitalisation ₹4.24The trillion है। दूसरी तिमाही के नतीजों के बाद,The near-term earnings projections और target prices कोThe revised downwards किया गया। कंपनीThe share price शुरू मेंThe rose लेकिन बाद मेंThe अधिकांशThe gains कोThe relinquish कर दिया।